Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Adenocarcinoma of Lung 2Sarcoma 1Neoplasm Metastasis 1

Interventions

Carboplatin 17Radiotherapy 13Paclitaxel 13Cisplatin 9Vinorelbine 5Pemetrexed 5Gemcitabine 5Docetaxel 5Mastectomy, Segmental 4Gefitinib 4Bevacizumab 4Taxes 3Radiation 3Etoposide 3ceritinib 2shark cartilage extract 1pembrolizumab 1pegfilgrastim 1lorlatinib 1lazertinib 1efaproxiral 1Vindesine 1Vinblastine 1Tirapazamine 1Therapeutics 1Thalidomide 1Surgical Procedures, Operative 1Nivolumab 1Neoadjuvant Therapy 1Ipilimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Adenocarcinoma of Lung × ceritinib × Clear all
NCT01828112 2025-02-07

LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib

Novartis

Phase 3 Completed
231 enrolled 33 charts
Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01828099 2025-01-16

LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer

Novartis

Phase 3 Completed
376 enrolled 34 charts 1 FDA
Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡